KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Shares Outstanding (Weighted Average): 2009-2024

Historic Shares Outstanding (Weighted Average) for Sarepta Therapeutics (SRPT) over the last 16 years, with Dec 2024 value amounting to $95.5 million.

  • Sarepta Therapeutics' Shares Outstanding (Weighted Average) rose 2.46% to $97.7 million in Q3 2025 from the same period last year, while for Jun 2025 it was $98.3 million, marking a year-over-year increase of 3.97%. This contributed to the annual value of $95.5 million for FY2024, which is 2.11% up from last year.
  • Per Sarepta Therapeutics' latest filing, its Shares Outstanding (Weighted Average) stood at $95.5 million for FY2024, which was up 2.11% from $93.5 million recorded in FY2023.
  • Sarepta Therapeutics' 5-year Shares Outstanding (Weighted Average) high stood at $95.5 million for FY2024, and its period low was $78.9 million during FY2020.
  • For the 3-year period, Sarepta Therapeutics' Shares Outstanding (Weighted Average) averaged around $92.3 million, with its median value being $93.5 million (2023).
  • Data for Sarepta Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY grew of 10.35% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Sarepta Therapeutics' Shares Outstanding (Weighted Average) stood at $78.9 million in 2020, then rose by 10.35% to $87.1 million in 2021, then grew by 0.81% to $87.8 million in 2022, then increased by 6.57% to $93.5 million in 2023, then rose by 2.11% to $95.5 million in 2024.